AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10389848 — intervention group
Group type: EXPERIMENTAL
Intervention: Trp64Arg variant in never-obese women (n=16)
Number of subjects: 42
Study 8902989 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidas D‐Di assay
Number of subjects: 171
Study 8902989 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant IA D‐Di assay
Number of subjects: 171
Study 8902989 — intervention group
Group type: COMPARATOR
Intervention: Latex agglutination technique
Number of subjects: 171
Study 8902989 — intervention group
Group type: COMPARATOR
Intervention: Nycocard D‐Dimer assay
Number of subjects: 171
Study 8902989 — intervention group
Group type: COMPARATOR
Intervention: Classic ELISA methods (Stago, Organon, Behring)
Number of subjects: 171
Study 1894763 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cimetidine (50 mg/hr IV)
Number of subjects: 12
Study 1894763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cimetidine (300 mg IV over 15 minutes every 6 hours)
Number of subjects: 12
Study 1894763 — intervention group
Group type: COMPARATOR
Intervention: Control (aminophylline 0.9 mg/kg/hr over 6 hours)
Number of subjects: 12
Study 6275987 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVP16 (regimen I)
Number of subjects: 109
Study 6275987 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVP16 followed by COMP (regimen II)
Number of subjects: 109
Study 6275987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation
Number of subjects: 109
Study 6275987 — intervention group
Group type: COMPARATOR
Intervention: Observation only (for cranial irradiation group)
Number of subjects: 109
Study 30993680 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccally absorbed prochlorperazine (BAP) 6 mg plus 2.25 mL saline IV placebo
Number of subjects: 80
Study 30993680 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prochlorperazine (IVP) 10 mg and buccally absorbed saccharine pill placebo
Number of subjects: 80
Study 30993680 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccally absorbed prochlorperazine (BAP)
Number of subjects: 80
Study 30993680 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prochlorperazine (IVP)
Number of subjects: 80
Study 29900913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (4 mg)
Number of subjects: 60
Study 29900913 — intervention group
Group type: COMPARATOR
Intervention: Curcumin (300 mg thrice daily)
Number of subjects: 60
Study 27217703 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma long noncoding RNAs (lncRNAs)
Number of subjects: 0
Study 25005901 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent involvement during anamnesis and recommendations for home exercises
Number of subjects: 53
Study 25005901 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' attitudes toward working with parents
Number of subjects: 53
Study 25005901 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for limited parent involvement
Number of subjects: 53
Study 21929834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum (6 g)
Number of subjects: 10
Study 21929834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19114869 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell-driven scheduled treatment interruption (STI)
Number of subjects: 329
Study 19114869 — intervention group
Group type: COMPARATOR
Intervention: Continuous HAART (control)
Number of subjects: 329
Study 17213964 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity (MOD, n = 13, 5 sessions per week, 30 min each, intensity 90 % of the anaerobic threshold)
Number of subjects: 39
Study 17213964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity (LOW, n = 13, 5 sessions per week, intensity 15 bpm below MOD)
Number of subjects: 39
Study 17213964 — intervention group
Group type: COMPARATOR
Intervention: Control (CO, n = 13, no training)
Number of subjects: 39
Study 17213964 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity (MOD)
Number of subjects: 39
Study 17213964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity (LOW)
Number of subjects: 39
Study 15878306 — intervention group
Group type: EXPERIMENTAL
Intervention: ICES (International Classification of Epileptic Seizures)
Number of subjects: 28
Study 15878306 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSS (Proposal of a New Diagnostic Scheme for Seizures)
Number of subjects: 28
Study 15878306 — intervention group
Group type: EXPERIMENTAL
Intervention: SSC (Semiological Seizure Classification)
Number of subjects: 28
Study 15878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience with epilepsy surgery
Number of subjects: 28
Study 15878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability analysis for ICES
Number of subjects: 28
Study 15878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability analysis for PDSS
Number of subjects: 28
Study 15878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability analysis for SSC
Number of subjects: 28
Study 15878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference questionnaire results
Number of subjects: 28
Study 12466187 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptive methods (specifics not provided)
Number of subjects: 0
Study 12466187 — intervention group
Group type: COMPARATOR
Intervention: Condoms
Number of subjects: 0
Study 12466187 — intervention group
Group type: COMPARATOR
Intervention: Vasectomy
Number of subjects: 0
Study 9607840 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g)
Number of subjects: 17
Study 9607840 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 17
Study 7694905 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT three times weekly
Number of subjects: 52
Study 7694905 — intervention group
Group type: COMPARATOR
Intervention: ECT twice weekly
Number of subjects: 52
Study 2151277 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 304
Study 2151277 — intervention group
Group type: COMPARATOR
Intervention: Zoladex
Number of subjects: 304
Study 638627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Coronary Care Unit (MCCU)
Number of subjects: 3340
Study 638627 — intervention group
Group type: COMPARATOR
Intervention: Routine transport
Number of subjects: 3340
Study 638627 — intervention group
Group type: COMPARATOR
Intervention: Routine ambulances (general practitioners' patients)
Number of subjects: 3340
Study 30242234 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle insulin sensitivity index (MISI)
Number of subjects: 640
Study 30242234 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic insulin resistance index (HIRI)
Number of subjects: 640
Study 30242234 — intervention group
Group type: EXPERIMENTAL
Intervention: Odd-chain/even-chain TAG ratio
Number of subjects: 640
Study 30242234 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-long-chain/long-chain TAG ratio
Number of subjects: 640
Study 30242234 — intervention group
Group type: EXPERIMENTAL
Intervention: TAG levels
Number of subjects: 640
Study 28056540 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's book about SHSe distributed to patients
Number of subjects: 7
Study 28056540 — intervention group
Group type: COMPARATOR
Intervention: No materials provided (Control group)
Number of subjects: 7
Study 25986137 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-patient intervention (n = 167)
Number of subjects: 503
Study 25986137 — intervention group
Group type: COMPARATOR
Intervention: Physician-only intervention (n = 183)
Number of subjects: 503
Study 25986137 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 153)
Number of subjects: 503
Study 25986137 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-patient intervention
Number of subjects: 503
Study 25986137 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 503
Study 23239301 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient haptic skills simulator (training on grasping, probing, and sweeping)
Number of subjects: 30
Study 20796077 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐6 polyunsaturated fatty acids (PUFA) diet
Number of subjects: 0
Study 20796077 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFA) diet
Number of subjects: 0
Study 19209987 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 3
Study 19209987 — intervention group
Group type: COMPARATOR
Intervention: Institutionalized children
Number of subjects: 3
Study 19209987 — intervention group
Group type: COMPARATOR
Intervention: Family-reared children
Number of subjects: 3
Study 19209987 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study 18044198 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 213
Study 15671129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral risperidone 2‐6 mg/day
Number of subjects: 75
Study 15671129 — intervention group
Group type: COMPARATOR
Intervention: Oral zuclopenthixol 20‐50 mg/day
Number of subjects: 75
Study 15671129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (risperidone and zuclopenthixol)
Number of subjects: 75
Study 15671129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral risperidone
Number of subjects: 75
Study 15671129 — intervention group
Group type: COMPARATOR
Intervention: Oral zuclopenthixol
Number of subjects: 75
Study 15671129 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 75
Study 12021218 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg once daily)
Number of subjects: 112000
Study 12021218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112000
Study 9535526 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-aided therapy
Number of subjects: 20
Study 9535526 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral manipulation of the impaired limb
Number of subjects: 20
Study 7656119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg for every 20 mg of fluoxetine
Number of subjects: 45
Study 7656119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 75 mg for every 20 mg of fluoxetine
Number of subjects: 45
Study 7656119 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (control group)
Number of subjects: 45
Study 2502789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.56 g/kg)
Number of subjects: 20
Study 2502789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 170521 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic inactivation with neutral red and light
Number of subjects: 96
Study 170521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 31056357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with intraoperative cerebral oximetry monitoring and intervention protocol for cerebral oxygen desaturation.
Number of subjects: 0
Study 31056357 — intervention group
Group type: COMPARATOR
Intervention: Control group with hidden cerebral oximetry data and no intervention protocol.
Number of subjects: 0
Study 30279332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mushroom diet
Number of subjects: 32
Study 30279332 — intervention group
Group type: COMPARATOR
Intervention: Meat diet
Number of subjects: 32
Study 29176684 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 26
Study 29176684 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 26
Study 26139640 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 52
Study 26139640 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg twice daily)
Number of subjects: 52
Study 21937420 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin pretreatment
Number of subjects: 60
Study 21937420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18312984 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified carbon dioxide
Number of subjects: 60
Study 18312984 — intervention group
Group type: COMPARATOR
Intervention: Standard cold dry gas (control group)
Number of subjects: 60
Study 16861054 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (40 min at moderate intensity, 5 times a week from 18 weeks gestation until birth)
Number of subjects: 0
Study 16861054 — intervention group
Group type: COMPARATOR
Intervention: Stretching (40 min without increasing heart rate to more than 10% of resting heart rate, 5 times a week from 18 weeks gestation until birth)
Number of subjects: 0
Study 12702550 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) 225,000 IU twice daily for 30 days
Number of subjects: 110
Study 12702550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 12702550 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Number of subjects: 110
Study 10787208 — intervention group
Group type: EXPERIMENTAL
Intervention: C-arm CT fluoroscopy
Number of subjects: 18
Study 10787208 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy
Number of subjects: 18
Study 8877242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine at a dose of 9.3 +/- 0.9 mg/kg/day
Number of subjects: 0
Study 8877242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine at a dose of 14.8 +/- 3.9 mg/kg/day
Number of subjects: 0
Study 1686656 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg remoxipride
Number of subjects: 11
Study 1686656 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg remoxipride
Number of subjects: 11
Study 1686656 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg remoxipride
Number of subjects: 11
Study 1686656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6628584 — intervention group
Group type: EXPERIMENTAL
Intervention: Becotide inhalation
Number of subjects: 17
Study 6628584 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol pretreatment followed by Becotide inhalation
Number of subjects: 17
Study 6628584 — intervention group
Group type: EXPERIMENTAL
Intervention: Becotide
Number of subjects: 17
Study 6628584 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Aldecine aerosols
Number of subjects: 17
Study 31017637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg orally twice daily
Number of subjects: 5022
Study 31017637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022
Study 30058377 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized dehydrated human amnion/chorion membrane (dHACM) injection
Number of subjects: 145
Study 30058377 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride placebo
Number of subjects: 145
Study 27783918 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term supplemental oxygen (24-hour oxygen for resting desaturation; oxygen during exercise and sleep for exercise-induced desaturation)
Number of subjects: 738
Study 27783918 — intervention group
Group type: COMPARATOR
Intervention: No long-term supplemental oxygen
Number of subjects: 738
Study 27783918 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term supplemental oxygen
Number of subjects: 738
Study 25358095 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cig groups
Number of subjects: 48
Study 25358095 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 48
Study 21933851 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (n = 61)
Number of subjects: 247
Study 21933851 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-only (intensification and maintenance therapy; n = 186)
Number of subjects: 247
Study 21933851 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation for patients with 11q23 aberrations (n = 18)
Number of subjects: 247
Study 21933851 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-only for patients with 11q23 aberrations (n = 49)
Number of subjects: 247
Study 21933851 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation for patients without 11q23 aberrations
Number of subjects: 247
Study 21933851 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-only for patients without 11q23 aberrations
Number of subjects: 247
Study 19637250 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling
Number of subjects: 266
Study 19637250 — intervention group
Group type: COMPARATOR
Intervention: No scalp cooling (Control)
Number of subjects: 266
Study 17607101 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD with fusion using a semirigid plate
Number of subjects: 20
Study 17607101 — intervention group
Group type: COMPARATOR
Intervention: Simple anterior microdiscectomy (ACD)
Number of subjects: 20
Study 16105246 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful irrelevant speech
Number of subjects: 4
Study 16105246 — intervention group
Group type: EXPERIMENTAL
Intervention: Road traffic noise
Number of subjects: 4
Study 16105246 — intervention group
Group type: COMPARATOR
Intervention: Quiet
Number of subjects: 4
Study 12398165 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide points
Number of subjects: 46
Study 12398165 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste
Number of subjects: 46
Study 12398165 — intervention group
Group type: COMPARATOR
Intervention: Free-floating (planktonic) cultures
Number of subjects: 46
Study 12398165 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm bacteria
Number of subjects: 46
Study 9952363 — intervention group
Group type: EXPERIMENTAL
Intervention: dideoxyinosine (ddI)
Number of subjects: 0
Study 9952363 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine+ddI
Number of subjects: 0
Study 9952363 — intervention group
Group type: COMPARATOR
Intervention: zidovudine monotherapy
Number of subjects: 0
Study 7477798 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.30 mg/kg IV induction, 0.02 mg/kg/min continuous infusion for 24-72 hours)
Number of subjects: 7
Study 7477798 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital (not detailed in dosage or duration)
Number of subjects: 7
Study 2154925 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated oral rhesus Rotavirus candidate vaccine (strain MMU 18006 [lot RRV‐1])
Number of subjects: 200
Study 2154925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7294770 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 201
Study 7294770 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 201
Study 30111253 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 62
Study 30111253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 28535707 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular pigment optical density (MPOD)
Number of subjects: 56
Study 27746305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dusquetide
Number of subjects: 0
Study 27746305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24793722 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate
Number of subjects: 1771
Study 24793722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1771
Study 22848006 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (1000 mg testosterone undecanoate, n=33)
Number of subjects: 67
Study 22848006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=34)
Number of subjects: 67
Study 20337081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual split bone technique
Number of subjects: 150
Study 20337081 — intervention group
Group type: COMPARATOR
Intervention: High speed turbine bodkin boneless technique
Number of subjects: 150
Study 17373972 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment
Number of subjects: 250
Study 17373972 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol 50 microg/g ointment
Number of subjects: 250
Study 15957724 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low dose oral midazolam (0.25 mg/kg) and low dose oral ketamine (3 mg/kg)
Number of subjects: 72
Study 15957724 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 72
Study 15957724 — intervention group
Group type: COMPARATOR
Intervention: Oral ketamine (6 mg/kg)
Number of subjects: 72
Study 12024143 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP/PTC
Number of subjects: 50
Study 12024143 — intervention group
Group type: EXPERIMENTAL
Intervention: MRCP
Number of subjects: 50
Study 12024143 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 50
Study 12024143 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 50
Study 12024143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MRCP and EUS
Number of subjects: 50
Study 9689426 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol/codeine fixed-dose combination (500 mg paracetamol and 30 mg codeine phosphate)
Number of subjects: 55
Study 9689426 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (50 mg tramadol hydrochloride)
Number of subjects: 55
Study 8580228 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy treatment for 1 week
Number of subjects: 26
Study 8580228 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy treatment for 2 weeks
Number of subjects: 26
Study 2669436 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 52
Study 2669436 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 1265780 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 1g Podophyllum/day after irradiation (128 patients)
Number of subjects: 256
Study 1265780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g Acethyl-homocystein-thiolactone (AHCT) prior to irradiation and Podophyllum after exposure (46 patients)
Number of subjects: 256
Study 1265780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 256
Study 30768673 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient multicomponent rehabilitation (3.5 weeks or 4+4 days)
Number of subjects: 334